Söndag 14 December | 14:29:25 Europe / Stockholm

Kalender

Est. tid*
2025-07-28 - Kvartalsrapport 2025-Q2
2025-05-07 - X-dag ordinarie utdelning EL 3.95 EUR
2025-04-30 - Extra Bolagsstämma
2025-04-30 - Årsstämma
2025-02-12 - Bokslutskommuniké 2024
2024-07-25 - Kvartalsrapport 2024-Q2
2024-05-03 - X-dag ordinarie utdelning EL 3.95 EUR
2024-04-30 - Extra Bolagsstämma
2024-04-30 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-07-26 - Kvartalsrapport 2023-Q2
2023-05-22 - X-dag ordinarie utdelning EL 3.23 EUR
2023-05-17 - Extra Bolagsstämma
2023-05-17 - Årsstämma
2023-03-10 - Bokslutskommuniké 2022
2022-07-29 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning EL 2.51 EUR
2022-05-25 - Extra Bolagsstämma
2022-05-25 - Årsstämma
2022-03-11 - Bokslutskommuniké 2021
2021-07-30 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag halvårsutdelning EL 1.08
2021-05-21 - Extra Bolagsstämma
2021-05-21 - Årsstämma
2021-03-12 - Bokslutskommuniké 2020
2020-12-23 - X-dag bonusutdelning EL 1.15
2020-06-25 - Extra Bolagsstämma
2020-06-25 - Årsstämma
2019-10-30 - Kvartalsrapport 2019-Q3

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-12 08:00:00

EssilorLuxottica to acquire Signifeye,
further growing its ophthalmology clinics footprint

Paris, France (12 December 2025) – EssilorLuxottica announced today the acquisition of Signifeye, a leading Belgian ophthalmology platform delivering top-tier patient care across 15 eye centers and clinics in the Flanders region.

The transaction comes soon after the recent acquisition of Optegra, a fast-growing and highly integrated ophthalmology platform in Europe operating over 70 clinics in the UK, Czech Republic, Poland, Slovakia and the Netherlands. While strengthening Optegra’s position in Europe, it also advances EssilorLuxottica’s med-tech trajectory and its ambition to pioneer the most advanced, integrated and expert-driven medical model, capable of addressing the full continuum of need, from prevention and early detection to specialized clinical management.

Offering both medically necessary ophthalmic treatments and elective vision procedures, the Signifeye platform provides the full spectrum of eye healthcare services. In line with Optegra, Signifeye has built a reputation for clinical excellence in the private sector, trusted care and industry-leading outcomes.

“With Signifeye joining EssilorLuxottica’s ecosystem, we strengthen our ability to deliver truly end-to-end eye care and redefine what medical excellence can be across the entire patient journey. By combining our medical and scientific innovation capabilities with Signifeye’s proven clinical excellence, we can meaningfully enhance the patient experience and empower people to live their best lives,” commented Francesco Milleri, Chairman and Chief Executive Officer, and Paul du Saillant, Deputy Chief Executive Officer at EssilorLuxottica.

“Joining forces with EssilorLuxottica and Optegra marks a transformative chapter for Signifeye. By combining their global leadership in vision care with our commitment to patient care and clinical excellence, we look forward to building the future of eye care together,” added Kathleen Moons, Chief Executive Officer at Signifeye.

The transaction is expected to close by Q1 2026.